HUMA Stock Overview
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Humacyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$8.04 |
| 52 Week Low | US$1.96 |
| Beta | 1.13 |
| 1 Month Change | 43.93% |
| 3 Month Change | -6.38% |
| 1 Year Change | -41.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -68.15% |
Recent News & Updates
Shareholder Returns
| HUMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.8% | -0.8% | 2.9% |
| 1Y | -41.0% | 4.5% | -8.5% |
Return vs Industry: HUMA underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: HUMA underperformed the US Market which returned -9.1% over the past year.
Price Volatility
| HUMA volatility | |
|---|---|
| HUMA Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HUMA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: HUMA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 146 | Laura Niklason | https://www.humacyte.com |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.
Humacyte, Inc. Fundamentals Summary
| HUMA fundamental statistics | |
|---|---|
| Market Cap | US$317.60m |
| Earnings (TTM) | US$34.34m |
| Revenue (TTM) | US$1.74m |
9.2x
P/E Ratio182.3x
P/S RatioIs HUMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HUMA income statement (TTM) | |
|---|---|
| Revenue | US$1.74m |
| Cost of Revenue | US$64.55m |
| Gross Profit | -US$62.81m |
| Other Expenses | -US$97.15m |
| Earnings | US$34.34m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.33 |
| Gross Margin | -3,605.68% |
| Net Profit Margin | 1,971.30% |
| Debt/Equity Ratio | 24.1% |
How did HUMA perform over the long term?
See historical performance and comparison